Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Stopped The study was terminated following an internal review of the company's research and development portfolio

Conditions

• Neoplasms

Interventions

• DRUG: Letetresgene autoleucel
• DRUG: Letetresgene autoleucel with pembrolizumab
• DRUG: Fludarabine
• DRUG: Cyclophosphamide
• DRUG: Pembrolizumab

Sponsor

GlaxoSmithKline

Collaborators

• [object Object]